Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Extra Pale who wrote (750)	1/12/2003 10:49:27 PM
From: Jibacoa	Read Replies (1) of 1005

GNVC Did pretty good from November 20( the date of my previous note.<g>) until its double top on December 11-December 12 at the 4.42 level. In November it said that a Phase II study of Biobypass angiogen showed significant positive results in patients with severe artery disease. GenVec said then that the Biobypass group showed "significant improvement in all endpoints". The stock bounced back (on an up-gap)from the $2.50 level on Thursday, but experienced some profit tacking on Friday. It needs to close above $3.50 to get off its present down-trend. Message 18256181 Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next